Area of Science:

• Nephrology
• Hematology
• Pharmacology

Context:

• Anemia is a frequent complication in chronic kidney disease (CKD) due to reduced erythropoietin (EPO) production and iron deficiency.
• Current treatments involve iron supplementation and recombinant EPO, with new iron formulations offering improved administration and efficacy.
• Hypoxia-inducible factor (HIF) prolyl-hydroxylase inhibitors represent a novel class of orally administered erythropoiesis-stimulating agents.

Purpose:

• To review recent advancements in anemia management for CKD patients.
• To evaluate novel iron formulations and HIF-prolyl-hydroxylase inhibitors as therapeutic options.
• To compare the efficacy and safety of these new agents against established treatments like recombinant EPO.

Summary:

• New oral iron formulations (ferric citrate, ferric carboxymaltose, ferric pyrophosphate citrate) enhance iron delivery and phosphate chelation.
• HIF-prolyl-hydroxylase inhibitors stabilize HIF, boosting endogenous EPO production and demonstrating non-inferiority to recombinant EPO in CKD patients.
• These inhibitors induce a greater decrease in hepcidin compared to injectable recombinant EPO, with currently reassuring safety profiles needing further long-term validation.

Impact:

• These developments offer improved treatment strategies for anemia in CKD, potentially enhancing patient outcomes and adherence.
• The introduction of oral HIF-prolyl-hydroxylase inhibitors provides a new therapeutic avenue with a potentially favorable impact on iron metabolism and anemia correction.
• Further long-term studies are essential to fully establish the safety and efficacy of HIF-prolyl-hydroxylase inhibitors in diverse CKD populations.